Clinical Trials Logo

Alagille Syndrome clinical trials

View clinical trials related to Alagille Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05543174 Active, not recruiting - Clinical trials for Alagille Syndrome (ALGS)

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Start date: January 16, 2023
Phase: Phase 3
Study type: Interventional

The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future. The participants will be treated with TAK-625 for up to the end of study (about 34 months). Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.

NCT ID: NCT05035030 Active, not recruiting - Alagille Syndrome Clinical Trials

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

ASSERT-EXT
Start date: September 3, 2021
Phase: Phase 3
Study type: Interventional

An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT)

NCT ID: NCT04729751 Active, not recruiting - Alagille Syndrome Clinical Trials

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

RISE
Start date: September 9, 2021
Phase: Phase 2
Study type: Interventional

This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children <12 months of age with Alagille Syndrome [ALGS] or Progressive Familial Intrahepatic Cholestasis [PFIC].

NCT ID: NCT02922751 Active, not recruiting - Portal Hypertension Clinical Trials

FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

FORCE
Start date: November 16, 2016
Phase:
Study type: Observational

Noninvasive monitoring of liver fibrosis is an unmet need within the clinical management of pediatric chronic liver disease. While liver biopsy is often used in the initial diagnostic evaluation, subsequent biopsies are rarely performed because of inherent invasiveness and risks. This study will evaluate the role of non-invasive FibroScan™ technology to detect and quantify liver fibrosis.